GenEdit
BreezeBio
South San Francisco, United States · Founded 2016 · $118.5M raised
- Headquarters
- South San Francisco, California
- Employees
- 51–200
- Founded
- 2016
- Business Model
- B2B
- Website
- genedit.com
- Total Funding
- $118.5M
- Last Round
- $60.0M Series BFeb 2026
- Rounds
- 4
About
GenEdit (now operating as BreezeBio) is a South San Francisco-based genetic medicine company developing nanoparticle delivery technology for gene therapy and gene editing applications. The company's proprietary NanoGalaxy platform provides a library of non-immunogenic nanoparticles that enable targeted delivery of genetic payloads to specific cells and tissues. GenEdit's lead program focuses on autoimmune disease and has established a multi-year collaboration with Genentech. The company rebranded to BreezeBio in 2026 to reflect its pipeline focus on autoimmune disease, including a Type 1 Diabetes program called BRZ-101.
Summary
GenEdit is a Biotech company based in South San Francisco, United States, founded in 2016. It has raised $118.5M in total across 4 rounds, most recently a $60.0M Series B round in Feb 2026. Investors include Eli Lilly, KTB Network and SK Holdings.
Tech & App Stack
4 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Feb 2026
Sign up to see all 4 rounds
Seed through Series B — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/genedit"><img src="https://indexed.vc/api/badge/company/genedit" alt="GenEdit on Indexed.vc" width="260" height="76" /></a>